Put companies on watchlist
Vita 34 AG
ISIN: DE000A0BL849
WKN: A0BL84
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Vita 34 AG · ISIN: DE000A0BL849 · EQS - adhoc news (54 News)
Country: Germany · Primary market: Germany · EQS NID: 1244399
28 October 2021 01:32PM

Vita 34 AG: Exchange Offer PBKM - 95% Minimum Acceptance Rate Exceeded


DGAP-Ad-hoc: Vita 34 AG / Key word(s): Mergers & Acquisitions/Capital Increase
Vita 34 AG: Exchange Offer PBKM - 95% Minimum Acceptance Rate Exceeded

28-Oct-2021 / 13:32 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF APPLICABLE LAWS OR REGULATIONS

Vita 34 AG: Exchange Offer PBKM - 95% Minimum Acceptance Rate Exceeded

Leipzig, 28 October 2021 - Vita 34 AG ("Vita 34") announces in connection with the voluntary public exchange offer by Vita 34 addressed to the shareholders of Polski Bank Komórek Macierzystych S.A., Warsaw, ("PBKM") that the total number of PBKM shares for which the exchange offer has been accepted as of 28 October 2021, 12.30 pm (CEST), plus the PBKM shares held by Vita 34 and its subsidiaries, plus the PBKM shares for which Vita 34 or its subsidiaries have entered into an agreement outside the exchange offer giving them the right to demand the transfer of title to such PBKM shares amounts to 9,090,625 PBKM shares. This corresponds to approximately 97.34% of the outstanding PBKM shares. Thus, the minimum acceptance rate of 95% of the PBKM shares under the exchange offer was exceeded and, subject to potential withdrawal rights, the relevant closing condition will therefore be fulfilled.

Subject to the fulfillment of the remaining closing conditions, the share exchange is expected to be completed until 15 November 2021. Based on the resolution of the extraordinary general meeting of Vita 34 held on 13 July 2021, the share capital of Vita 34 is expected to increase from EUR 4,145,959 by at least EUR 11,817,812 to at least EUR 15,963,771 by way of issuance of at least 11,817,812 new no-par-value registered shares.

Important Information

This announcement does neither constitute an offer to exchange or purchase nor the solicitation of an offer to exchange or purchase any securities. Moreover, this announcement does neither constitute an offer to buy nor the solicitation of an offer to buy any securities in PBKM or Vita 34. The final terms and further provisions regarding the Exchange Offer will be included in a securities prospectus once it has been approved by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht). Investors and holders of PBKM shares are strongly recommended to read the securities prospectus and all other documents in connection with the Exchange Offer as soon as they are published, as they will contain important information. Vita 34 may not initiate the Exchange Offer at all.

Subject to the exceptions described in the securities prospectus and any exceptions granted by the relevant regulatory authorities, an Exchange Offer is not being made, directly or indirectly, in or into those jurisdictions where to do so would constitute a violation pursuant to the laws of such jurisdiction.

In particular, the Vita 34 shares that are intended to be transferred to PBKM shareholders as consideration (the "Vita 34 Offer Shares") have not been, and will not be, registered under the United States Securities Act of 1933 as amended, (the "Securities Act"), or under the securities laws of any state, district or other jurisdiction of the U.S.A. The Vita 34 Offer Shares may not be offered, sold or delivered, directly or indirectly, to PBKM shareholders located with a domicile, registered office or habitual abode in the U.S.A. (the "U.S. Shareholders"), or to any agents, appointees, trustees, custodian banks or other persons acting for the account of benefit of any U.S. Shareholders, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.




Contact:
Dr. Wolfgang Knirsch (CEO), Andreas Schafhirt (CFO)

28-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: ir@vita34.de
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1244399

 
End of Announcement DGAP News Service

1244399  28-Oct-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1244399&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Vita 34 AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.